Article info
PDFPostScript
Correspondence
Authors' response: ‘Focusing on HER2 as a potential therapeutic target in primary ovarian mucinous carcinomas’
- Correspondence to Dr Gkeok Stzuan Diana Lim, Department of Pathology, National University Health System and National University of Singapore, 5 Lower Kent Ridge Road, Singapore 119074, Republic of Singapore; diana_gz_lim{at}nuhs.edu.sg
Citation
Authors' response: ‘Focusing on HER2 as a potential therapeutic target in primary ovarian mucinous carcinomas’
Publication history
- First published January 28, 2012.
Online issue publication
July 07, 2020
Article Versions
- Previous version (7 July 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.